Posted in | Nanomedicine | Nanobusiness

Novavax Presents RSV Nanoparticle Vaccine Preclinical Findings at ISRVI 2013

Novavax, Inc. reported that David C. Flyer, Ph.D., Director of Preclinical Development at Novavax, presented recent preclinical findings from the company's respiratory syncytial virus (RSV) vaccine development program at the XV International Symposium on Respiratory Viral Infections in Rotterdam, the Netherlands.

He reported that in preclinical studies, Novavax' RSV vaccine candidate induced anti-RSV antibodies capable of neutralizing RSV in vitro and significantly reduced infectious RSV in a cotton rat challenge model. Further, in both clinical and preclinical studies, he reported that palivizumab-competing antibodies were generated at titers significantly above that found to be protective in both humans and cottons rats.

Dr. Flyer stated during his presentation: "Both the human and cotton rat data suggest that our RSV vaccine candidate induced robust antibody responses with activity similar to palivizumab, which is a licensed anti-RSV monoclonal antibody indicated for the prevention of RSV disease in at-risk children and infants. These data provide further scientific evidence that our vaccine candidate may have the potential to safely protect infants in the first few months of life, where morbidity and mortality from RSV is greatest, as well as other affected populations including pediatric and elderly patients."

In October 2012, the company initiated two separate dose-ranging clinical trials, one in women of child bearing age and the other in elderly adults. The first trial is a randomized, blinded, placebo-controlled Phase II clinical trial evaluating the safety and immunogenicity of two dose levels of the RSV vaccine candidate with and without an aluminum phosphate adjuvant, with 330 women of childbearing age enrolled. Top-line data from this trial are expected to be announced in April 2013. The second trial is a randomized, blinded, placebo-controlled Phase I clinical trial evaluating the safety and immunogenicity of two doses of the RSV vaccine candidate, also with and without aluminum phosphate as an adjuvant, with 220 elderly adults enrolled. Top-line data from this trial are expected to be reported later in the second quarter of 2013.

Source: http://www.novavax.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Novavax Inc.. (2019, February 11). Novavax Presents RSV Nanoparticle Vaccine Preclinical Findings at ISRVI 2013. AZoNano. Retrieved on November 11, 2019 from https://www.azonano.com/news.aspx?newsID=26888.

  • MLA

    Novavax Inc.. "Novavax Presents RSV Nanoparticle Vaccine Preclinical Findings at ISRVI 2013". AZoNano. 11 November 2019. <https://www.azonano.com/news.aspx?newsID=26888>.

  • Chicago

    Novavax Inc.. "Novavax Presents RSV Nanoparticle Vaccine Preclinical Findings at ISRVI 2013". AZoNano. https://www.azonano.com/news.aspx?newsID=26888. (accessed November 11, 2019).

  • Harvard

    Novavax Inc.. 2019. Novavax Presents RSV Nanoparticle Vaccine Preclinical Findings at ISRVI 2013. AZoNano, viewed 11 November 2019, https://www.azonano.com/news.aspx?newsID=26888.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit